Personalis (PSNL) vs. Its Competitors Financial Comparison

Personalis (NASDAQ:PSNL) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Personalis to similar businesses based on the strength of its dividends, earnings, profitability, valuation, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Personalis and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1	7	3	0	2.18
Personalis Competitors	943	3157	5465	175	2.50

Personalis presently has a consensus target price of $14.54, suggesting a potential downside of 9.18%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 8.90%. Given Personalis’ peers stronger consensus rating and higher probable upside, analysts clearly believe Personalis has less favorable growth aspects than its peers.

Volatility & Risk

Personalis has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Personalis’ peers have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Personalis and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Personalis	$69.65 million	-$81.27 million	-14.68
Personalis Competitors	$2.29 billion	$55.11 billion	-0.30

Personalis’ peers have higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

61.9% of Personalis shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Personalis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Personalis Competitors	-540.86%	-166.48%	-13.59%

Summary

Personalis peers beat Personalis on 9 of the 13 factors compared.

Personalis Company Profile

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.